Press Release

ANUPAM RASAYAN INDIA LTD. ARILSLDSTX20261106077 Date: November 06, 2026 To, T o , BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai-400001, India Mumbai-400051, India SCRIP CODE: 543275 SYMBOL: ANURAS Dear Sir/Madam, Subject: Intimation of Press Release. Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release to be issued by Anupam Rasayan India Limited (the “Company”) today i.e., November 06, 2026, regarding the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, approved by the Board of Directors of the Company. This Press Release will also be hosted on the website of the Company at www.anupamrasayan.com. We request you to kindly take note the same. Thanking you, Yours Faithfully, For Anupam Rasayan India Limited Anand Desai Managing Director DIN: 00038442 Encl.: As above Registered Office: Tel. : +91-261-2398991-95 Office Nos. 1101 to 1107, 11th Floor, Icon Rio, Fax : +91-261-2398996 Behind Icon Business Centre, Dumas Road, E-mail : office@anupamrasayan.com Surat-395007, Gujarat, India. Website : www.anupamrasayan.com CIN - L24231GJ2003PLC042988 Anupam Rasayan India Limited Q2 & H1 FY27 Earnings Press Release Surat, November 6th, 2026: Anupam Rasayan India Limited (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and half year ended September 30th, 2026. Particulars (Rs. In Crs) Q2FY27 Q2FY26 YoY (%) H1 FY27 H1 FY26 YoY (%) Total Revenue 821 739 11% 1,489 1,230 21% EBITDA 202 144 41% 377 273 38% EBITDA Margin 25% 19% 25% 22% PAT 65 57 14% 116 106 10% Consolidated Financial Highlights for Half-year ended September 30th, 2026: ▪ Total Revenue for H1FY27 was Rs. 1,489 Cr as compared to Rs.1,230 Cr in H1FY26; up 21% YoY ▪ EBITDA (incl. other income) came in at Rs.377 Cr in H1FY27 as against Rs.273 Cr in H1FY26; up 38% YoY, translating into EBITDA margin of 25% for the Half year. ▪ Profit After Tax stood at Rs. 116 Cr in H1FY27 as compared to Rs. 106 Cr in H1FY26. Consolidated Financial Highlights for Quarter ended September 30th, 2026: ▪ Total Revenue for Q2FY27 was Rs. 821 Cr as compared to Rs. 739 Cr in Q2FY26; up 11% YoY. ▪ EBITDA (incl. other income) came in at Rs.202 Cr in Q2FY27 as against Rs.144 Cr in Q2FY26; up 41% YoY, translating into EBITDA margin of 25% for Q2FY27. ▪ Profit After Tax stood at Rs.65 Cr in Q2FY27 as compared to Rs.57 Cr in Q2FY26. Commenting on the performance, Mr. Anand Desai, Managing Director, Anupam Rasayan India Limited, said, “H1 FY27 was marked by steady progress across our strategic priorities, expansion into new end markets and continued strengthening of our business portfolio. We are pleased to have achieved our highest-ever quarterly consolidated revenue during Q2 FY27, reflecting the resilience of our diversified business and the progress made across key segments. Our focus continue to remain on building a globally integrated specialty chemicals platform by deepening relationships with existing customers, expanding into new applications and strengthening our capabilities across Pharmaceuticals, Performance Materials and other specialised segments. During the quarter, we signed a six-year long-term supply agreement with a US-based speciality metal manufacturer. This marks an important step towards establishing our presence in the geological resources sector, diversifying our customer base and building a long-term strategic partnership with a global customer. We also successfully completed the acquisition of a 50.07% stake in Bliss GVS Pharma, securing a controlling interest and marking a significant step in our vision of building a diversified pharmaceutical platform. The acquisition brings complementary capabilities in finished dosage formulations and provides opportunities to strengthen our presence across the pharmaceutical value chain, leverage operational and commercial synergies and expand our growth opportunities. Going forward, we remain focused on disciplined execution, optimal utilization of our capital employed, successful integration of our strategic investments and continuous enhancement of our manufacturing and technological capabilities. We believe these initiatives will strengthen our business resilience, support sustainable growth and create long-term value for all stakeholders.” About Anupam Rasayan India Limited Anupam Rasayan India Limited (Anupam) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the specialty chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Performance Materials comprising Electronics & EV Chemicals and Polymers. It is currently manufacturing products for over 200+ domestic and international customers. Anupam operates via its 14 manufacturing facilities, with 6 facilities located in Gujarat, 6 facilities in Maharastra, 1in Tamil Nadu and 1 in U.S. with an aggregate installed capacity of ~2,00,000+ MT for Speciality Chemicals and 4,800+ Mn Units for Pharmaceutical Formulations as of September 30, 2026. Anupam offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers. For more information, please contact: Company Details Investor Relations Advisors Anupam Rasayan India Limited Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa CIN: L24231GJ2003PLC042988 Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net www.anupamrasayan.com Mobile No – 9619595686 / 9819494608 www.sgapl.net DISCLAIMER: Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Anupam Rasayan India Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.